Skip to main content

Peer Review reports

From: Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group

Original Submission
2 Oct 2009 Submitted Original manuscript
16 Nov 2009 Reviewed Reviewer Report - Pankaj Hari
20 Nov 2009 Reviewed Reviewer Report - Therese Jungraithmayr
2 Dec 2009 Author responded Author comments - Howard Trachtman
Resubmission - Version 2
2 Dec 2009 Submitted Manuscript version 2
3 Dec 2009 Author responded Author comments - Howard Trachtman
Resubmission - Version 3
3 Dec 2009 Submitted Manuscript version 3
21 Dec 2009 Reviewed Reviewer Report - Pankaj Hari
22 Dec 2009 Reviewed Reviewer Report - Therese Jungraithmayr
15 Jan 2010 Author responded Author comments - Howard Trachtman
Resubmission - Version 4
15 Jan 2010 Submitted Manuscript version 4
25 Jan 2010 Author responded Author comments - Howard Trachtman
Resubmission - Version 5
25 Jan 2010 Submitted Manuscript version 5
Resubmission - Version 6
Submitted Manuscript version 6
27 Jan 2010 Author responded Author comments - Howard Trachtman
Resubmission - Version 7
27 Jan 2010 Submitted Manuscript version 7
Publishing
29 Jan 2010 Editorially accepted
29 Jan 2010 Article published 10.1186/1471-2369-11-2

You can find further information about peer review here.

Back to article page